Literature DB >> 1546335

Growth plate injury of the long bones in treated beta-thalassemia.

C Orzincolo1, P N Scutellari, G Castaldi.   

Abstract

In 12 patients affected by thalassemia major who received an intensive transfusion regimen combined with continuous iron chelation therapy (desferrioxamine 50-80 mg/kg daily), radiologic abnormalities of the long bones were observed similar to those observed in rickets and scurvy. These abnormalities were associated with a growth retardation. The pathogenesis of these lesions is uncertain, but probably the toxic effect of desferrioxamine plays an important role in their development. A relative deficiency of vitamins D and/or C cannot be entirely excluded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546335     DOI: 10.1007/bf00243093

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  20 in total

1.  TRANSFUSION THERAPY IN COOLEY'S ANEMIA: GROWTH AND HEALTH AS RELATED TO LONG-RANGE HEMOGLOBIN LEVELS. A PROGRESS REPORT.

Authors:  I J WOLMAN
Journal:  Ann N Y Acad Sci       Date:  1964-10-07       Impact factor: 5.691

2.  Hypertransfusion regimen in patients with Cooley's anemia.

Authors:  S Piomelli; M H Karpatkin; M Arzanian; M Zamani; M H Becker; N Geneiser; S J Danoff; W J Kuhns
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

3.  Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen.

Authors:  S Piomelli; S J Danoff; M H Becker; M J Lipera; S F Travis
Journal:  Ann N Y Acad Sci       Date:  1969-11-20       Impact factor: 5.691

4.  The radiographic appearances following adequate transfusion in beta-thalassaemia.

Authors:  P N Scutellari; C Orzincolo; F Franceschini; B Bagni
Journal:  Skeletal Radiol       Date:  1989       Impact factor: 2.199

5.  Vitamin C and iron.

Authors:  A W Nienhuis
Journal:  N Engl J Med       Date:  1981-01-15       Impact factor: 91.245

6.  Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.

Authors:  S De Virgiliis; P Cossu; C Toccafondi; G Sanna; F Frau; R Lobrano; G Cornacchia; A Nucaro; A Loi; F Bertolino; A Cao
Journal:  Am J Pediatr Hematol Oncol       Date:  1983

7.  Deferoxamine-induced growth retardation in patients with thalassemia major.

Authors:  S De Virgiliis; M Congia; F Frau; F Argiolu; G Diana; F Cucca; A Varsi; G Sanna; G Podda; M Fodde
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

8.  Reassessment of the use of desferrioxamine B in iron overload.

Authors:  R D Propper; S B Shurin; D G Nathan
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

9.  Studies of marginal zinc deprivation in rhesus monkeys. V. Fetal and infant skeletal effects.

Authors:  J C Leek; J B Vogler; M E Gershwin; M S Golub; L S Hurley; A G Hendrickx
Journal:  Am J Clin Nutr       Date:  1984-12       Impact factor: 7.045

10.  Serum 1,25 dihydroxyvitamin D and osteocalcin concentrations in thalassaemia major.

Authors:  P Dandona; R K Menon; S Houlder; M Thomas; A V Hoffbrand; D M Flynn
Journal:  Arch Dis Child       Date:  1987-05       Impact factor: 3.791

View more
  7 in total

1.  Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients.

Authors:  M J Hartkamp; P S Babyn; F Olivieri
Journal:  Pediatr Radiol       Date:  1993

Review 2.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

3.  MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.

Authors:  T T Miller; G Caldwell; J J Kaye; S Arkin; S Burke; P W Brill
Journal:  Pediatr Radiol       Date:  1993

4.  Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia.

Authors:  M Hatori; J Sparkman; C C Teixeira; M Grynpas; J Nervina; N Olivieri; I M Shapiro
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

5.  Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.

Authors:  Hadeel M Seif El Dien; Reem I Esmail; Rania E Magdy; Hala M Lotfy
Journal:  Pediatr Radiol       Date:  2013-04-06

6.  Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.

Authors:  Mohamed Abdel Malik Hassan; Omar Atef Tolba
Journal:  Electron Physician       Date:  2016-05-25

7.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.